Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical company headquartered in Cambridge, UK, operates in over 130 ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...

A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential ...

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and ...